1. At a Glance – The SME Pharma That Woke Up and Chose Complexity
Sotac Pharmaceuticals Ltd is that classic Indian SME pharma story where the product list is longer than your Netflix watchlist, the client list looks suspiciously impressive, and the balance sheet quietly whispers, “working capital mujhe chhod do.” With a market cap of ₹143 crore, a current price of ₹130, and a 3-month return of ~19.8%, Sotac has suddenly started attracting eyeballs — not because it’s sexy, but because it’s busy. Very busy.
Latest Half-Yearly Results (H1 FY26) show September 2025 quarter sales of ₹37.01 crore and PAT of ₹2.45 crore, despite a sharp QoQ sales decline of ~29.6%. Profit, however, decided to flex with a ~28.3% QoQ growth, thanks to margin expansion and other income doing cardio. ROE at ~15.7%, ROCE ~15.1%, Debt-to-Equity ~0.69, and P/E ~16.7x — not screaming cheap, not screaming expensive, just standing there confidently like a mid-batsman on 47 runs.
The company operates in manufacturing-heavy pharma, exports to 20+ countries, services 162 pharma clients, and lives largely off contract manufacturing. If this was a Bollywood character, Sotac would be the reliable supporting actor who shows up in every big film but never gets the poster.
Curious yet? Good. You should be.
2. Introduction – Welcome to the World of “We Manufacture Everything” Pharma
Sotac Pharmaceuticals Ltd was incorporated in 2015, which means it is young enough to still be ambitious and old enough to have learned a few painful lessons — mostly about receivables. The company manufactures a wide range of pharmaceutical products across almost every therapeutic area that exists between fever and fungal infections. Anti-diabetic? Yes. Cardiac? Yes. Antibiotics (beta and non-beta)? Obviously. Dermatology? Throw it in. Nutraceuticals? Why not.
This is not a “one blockbuster molecule” story. Sotac’s business model is more like a thali — lots of items, moderate portions, and repeat customers. The company primarily earns from manufacturing sales (~99% of FY24 revenue), while job work and other income play a minor cameo.
Sotac operates both non-beta-lactam and beta-lactam manufacturing, with beta-lactam operations conducted in collaboration with Sotac Healthcare Private Limited. On top of that, it has subsidiaries like Sotac Lifesciences Private Limited, which is now dabbling in nutraceuticals and food products — because pharma companies eventually get bored and want to sell protein powders too.
The export exposure, especially to the US market, adds spice but also compliance pressure. And yet, despite all this complexity, Sotac has managed to grow 5-year profit CAGR of ~150% and 5-year sales CAGR of ~28%. Not bad for a company that most investors discovered only after its SME IPO in April 2023, where it raised ₹33.30 crore.
So the obvious question — is this a scalable pharma manufacturer or just a very efficient job worker with a long Excel sheet?
Let’s dig.
3. Business Model – WTF Do They Even Do (And Why So Many Tablets?)
Imagine explaining Sotac to a lazy but intelligent investor over cutting chai.
Sotac doesn’t invent blockbuster drugs. It manufactures formulations for other pharma companies — either on a contract manufacturing or loan license basis. Translation: other pharma brands own the marketing, Sotac owns the machines, manpower, and compliance headaches.
Core Verticals:
- Non-Beta-Lactam Manufacturing: Tablets, capsules, oral liquids, dry syrups, ointments, creams, lotions.
- Beta-Lactam Manufacturing: Tablets, capsules, oral liquids, dry syrups — executed via Sotac Healthcare Pvt Ltd.
- Molecule R&D: Limited but relevant — formulation development rather than discovery.
- Nutraceuticals & Food Products: Via Sotac Lifesciences Pvt Ltd, contract-based manufacturing.
Production Muscle:
Beta-lactam facility capacity (installed):
- 32.40 crore tablets/year
- 21.60 crore capsules/year
- 2.16 crore dry syrup bottles/year
That’s not small. That’s “we-need-orders-to-keep-machines-running-24×7” scale.
Revenue Mix (FY24):
- Manufacturing sales ~99%
- Job work & other income ~1%
- Product-wise:
- Tablets ~94%
- Capsules ~4%
- Ointments & liquids ~1%
The client
